Press Releases

Havn Life will develop methods for safe, standardized, quality- controlled production of medical compounds extracted from the Psilocybe spp. mushroom September 10, 2020 Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants […]

Havn Life Sciences will trade on the CSE under the Ticker Symbol HAVN September 8, 2020 Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that

September 4, 2020 Vancouver, BC – Havn Life Sciences Inc. (the “Company” or “Havn Life”), is pleased to announce that it has successfully completed its acquisition of HAVN Research Inc. (“HAVN Research”), acquiring 100% of the outstanding shares of HAVN Research (the “Acquisition Transaction”).  HAVN Research is a biotechnology company engaged in the business of the

Gary Leong has over 30 years’ experience in the Pharmaceutical and Natural Health Products Industry.   July 6, 2020 Vancouver, BC – Havn Life Sciences Inc. (the “Company” or “Havn Life”), announces the appointment of Gary Leong as Chief Science Officer of Havn Life. Mr. Leong has over thirty (30) years of experience in the

Havn Life Sciences Inc. is focused on the standardized, quality-controlled extraction of psychoactive compounds including psilocybin from plants and fungi, and the development of natural health care products from novel compounds. June 25, 2020 Vancouver, BC – Havn Life Sciences Inc. (the “Company” or “Havn Life”), announces launch and filing of its preliminary prospectus. Havn